Logo image of IVVD

INVIVYD INC (IVVD) Stock Fundamental Analysis

NASDAQ:IVVD - Nasdaq - US00534A1025 - Common Stock - Currency: USD

0.39  +0 (+1.22%)

After market: 0.3989 +0.01 (+2.28%)

Fundamental Rating

2

IVVD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. IVVD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. IVVD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IVVD has reported negative net income.
In the past year IVVD has reported a negative cash flow from operations.
IVVD Yearly Net Income VS EBIT VS OCF VS FCFIVVD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

With a Return On Assets value of -139.04%, IVVD is not doing good in the industry: 83.19% of the companies in the same industry are doing better.
With a Return On Equity value of -270.72%, IVVD is not doing good in the industry: 72.57% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -139.04%
ROE -270.72%
ROIC N/A
ROA(3y)-62.07%
ROA(5y)N/A
ROE(3y)-73.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IVVD Yearly ROA, ROE, ROICIVVD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IVVD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IVVD Yearly Profit, Operating, Gross MarginsIVVD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, IVVD has more shares outstanding
IVVD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IVVD Yearly Shares OutstandingIVVD Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 20M 40M 60M 80M 100M
IVVD Yearly Total Debt VS Total AssetsIVVD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

IVVD has an Altman-Z score of -11.47. This is a bad value and indicates that IVVD is not financially healthy and even has some risk of bankruptcy.
IVVD's Altman-Z score of -11.47 is on the low side compared to the rest of the industry. IVVD is outperformed by 77.70% of its industry peers.
IVVD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.47
ROIC/WACCN/A
WACCN/A
IVVD Yearly LT Debt VS Equity VS FCFIVVD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 1.92 indicates that IVVD should not have too much problems paying its short term obligations.
With a Current ratio value of 1.92, IVVD is not doing good in the industry: 77.17% of the companies in the same industry are doing better.
A Quick Ratio of 1.58 indicates that IVVD should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.58, IVVD is doing worse than 81.06% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.58
IVVD Yearly Current Assets VS Current LiabilitesIVVD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

IVVD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -41.01%.
EPS 1Y (TTM)-41.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, IVVD will show a very strong growth in Earnings Per Share. The EPS will grow by 34.32% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y12.65%
EPS Next 2Y39.06%
EPS Next 3Y31.98%
EPS Next 5Y34.32%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IVVD Yearly Revenue VS EstimatesIVVD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
IVVD Yearly EPS VS EstimatesIVVD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IVVD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IVVD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IVVD Price Earnings VS Forward Price EarningsIVVD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IVVD Per share dataIVVD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

IVVD's earnings are expected to grow with 31.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.06%
EPS Next 3Y31.98%

More info and screens

0

5. Dividend

5.1 Amount

IVVD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INVIVYD INC

NASDAQ:IVVD (1/30/2025, 5:33:56 PM)

After market: 0.3989 +0.01 (+2.28%)

0.39

+0 (+1.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners78.39%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner Change0%
Market Cap46.65M
Analysts80
Price Target6.01 (1441.03%)
Short Float %4.14%
Short Ratio3.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.6%
Min EPS beat(2)-48.15%
Max EPS beat(2)-5.04%
EPS beat(4)1
Avg EPS beat(4)-22.05%
Min EPS beat(4)-55.17%
Max EPS beat(4)20.17%
EPS beat(8)3
Avg EPS beat(8)-7.09%
EPS beat(12)6
Avg EPS beat(12)-0.48%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-61.11%
Min Revenue beat(2)-66.54%
Max Revenue beat(2)-55.69%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.56%
PT rev (3m)-31.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-282.6%
EPS NY rev (1m)0%
EPS NY rev (3m)-69.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-90.69%
Revenue NY rev (1m)3.11%
Revenue NY rev (3m)-85.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.03
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-1.96
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-1.61
FCFYN/A
OCF(TTM)-1.61
OCFYN/A
SpS0.1
BVpS0.7
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -139.04%
ROE -270.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.07%
ROA(5y)N/A
ROE(3y)-73.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.89%
Cap/Sales 1.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.92
Quick Ratio 1.58
Altman-Z -11.47
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-41.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.67%
EPS Next Y12.65%
EPS Next 2Y39.06%
EPS Next 3Y31.98%
EPS Next 5Y34.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.95%
EBIT Next 3Y23.26%
EBIT Next 5Y17.96%
FCF growth 1Y21.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.84%
OCF growth 3YN/A
OCF growth 5YN/A